S&P 500   3,243.45 (-2.29%)
DOW   26,851.62 (-2.91%)
QQQ   264.21 (-1.00%)
AAPL   107.07 (+0.22%)
MSFT   199.94 (-0.22%)
FB   248.10 (-1.75%)
GOOGL   1,427.32 (-1.64%)
AMZN   2,904.48 (-1.71%)
NVDA   492.86 (+1.08%)
TSLA   442.90 (+0.17%)
BABA   271.13 (-0.47%)
CGC   15.61 (-4.58%)
GE   6.26 (-9.01%)
MU   49.09 (-3.25%)
AMD   76.85 (+2.56%)
T   28.33 (-2.07%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.78 (-1.95%)
NFLX   480.00 (+2.14%)
DIS   124.31 (-3.36%)
BAC   24.12 (-4.32%)
BA   156.69 (-2.76%)
S&P 500   3,243.45 (-2.29%)
DOW   26,851.62 (-2.91%)
QQQ   264.21 (-1.00%)
AAPL   107.07 (+0.22%)
MSFT   199.94 (-0.22%)
FB   248.10 (-1.75%)
GOOGL   1,427.32 (-1.64%)
AMZN   2,904.48 (-1.71%)
NVDA   492.86 (+1.08%)
TSLA   442.90 (+0.17%)
BABA   271.13 (-0.47%)
CGC   15.61 (-4.58%)
GE   6.26 (-9.01%)
MU   49.09 (-3.25%)
AMD   76.85 (+2.56%)
T   28.33 (-2.07%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.78 (-1.95%)
NFLX   480.00 (+2.14%)
DIS   124.31 (-3.36%)
BAC   24.12 (-4.32%)
BA   156.69 (-2.76%)
S&P 500   3,243.45 (-2.29%)
DOW   26,851.62 (-2.91%)
QQQ   264.21 (-1.00%)
AAPL   107.07 (+0.22%)
MSFT   199.94 (-0.22%)
FB   248.10 (-1.75%)
GOOGL   1,427.32 (-1.64%)
AMZN   2,904.48 (-1.71%)
NVDA   492.86 (+1.08%)
TSLA   442.90 (+0.17%)
BABA   271.13 (-0.47%)
CGC   15.61 (-4.58%)
GE   6.26 (-9.01%)
MU   49.09 (-3.25%)
AMD   76.85 (+2.56%)
T   28.33 (-2.07%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.78 (-1.95%)
NFLX   480.00 (+2.14%)
DIS   124.31 (-3.36%)
BAC   24.12 (-4.32%)
BA   156.69 (-2.76%)
S&P 500   3,243.45 (-2.29%)
DOW   26,851.62 (-2.91%)
QQQ   264.21 (-1.00%)
AAPL   107.07 (+0.22%)
MSFT   199.94 (-0.22%)
FB   248.10 (-1.75%)
GOOGL   1,427.32 (-1.64%)
AMZN   2,904.48 (-1.71%)
NVDA   492.86 (+1.08%)
TSLA   442.90 (+0.17%)
BABA   271.13 (-0.47%)
CGC   15.61 (-4.58%)
GE   6.26 (-9.01%)
MU   49.09 (-3.25%)
AMD   76.85 (+2.56%)
T   28.33 (-2.07%)
F   6.86 (-5.12%)
ACB   6.34 (-2.91%)
GILD   63.78 (-1.95%)
NFLX   480.00 (+2.14%)
DIS   124.31 (-3.36%)
BAC   24.12 (-4.32%)
BA   156.69 (-2.76%)
Log in
NASDAQ:NXTC

NextCure Stock Forecast, Price & News

$9.06
-0.51 (-5.33 %)
(As of 09/21/2020 01:54 PM ET)
Add
Compare
Today's Range
$9.04
Now: $9.06
$9.27
50-Day Range
$8.32
MA: $9.14
$10.04
52-Week Range
$8.00
Now: $9.06
$109.00
Volume5,576 shs
Average Volume477,658 shs
Market Capitalization$249.30 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.55
There is no company description available for NextCure Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
CUSIPN/A
CIKN/A
Phone240-399-4900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.35 million
Book Value$14.13 per share

Profitability

Net Income$-33,740,000.00

Miscellaneous

EmployeesN/A
Market Cap$249.30 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$9.06
-0.51 (-5.33 %)
(As of 09/21/2020 01:54 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NextCure (NASDAQ:NXTC) Frequently Asked Questions

How has NextCure's stock price been impacted by Coronavirus (COVID-19)?

NextCure's stock was trading at $38.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NXTC shares have decreased by 76.3% and is now trading at $9.06.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of NextCure?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NextCure
.

When is NextCure's next earnings date?

NextCure is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for NextCure
.

How were NextCure's earnings last quarter?

NextCure Inc (NASDAQ:NXTC) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.03. NextCure had a negative net margin of 65.22% and a negative return on equity of 8.43%.
View NextCure's earnings history
.

What price target have analysts set for NXTC?

9 Wall Street analysts have issued 12 month price objectives for NextCure's shares. Their forecasts range from $11.00 to $87.00. On average, they anticipate NextCure's share price to reach $32.70 in the next year. This suggests a possible upside of 260.9% from the stock's current price.
View analysts' price targets for NextCure
.

Are investors shorting NextCure?

NextCure saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,970,000 shares, an increase of 8.8% from the August 15th total of 1,810,000 shares. Based on an average daily volume of 857,800 shares, the short-interest ratio is currently 2.3 days. Currently, 12.1% of the company's stock are sold short.
View NextCure's Short Interest
.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Kadmon (KDMN), Novan (NOVN), OrganiGram (OGI), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

When did NextCure IPO?

(NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

Who are NextCure's major shareholders?

NextCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Great Point Partners LLC (3.63%), Cormorant Asset Management LP (2.52%), Hillhouse Capital Advisors LTD. (2.32%), Jennison Associates LLC (1.69%), Matthews International Capital Management LLC (0.92%) and Federated Hermes Inc. (0.41%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan.
View institutional ownership trends for NextCure
.

Which major investors are selling NextCure stock?

NXTC stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Great Point Partners LLC, Marshall Wace North America L.P., Bank of America Corp DE, Cormorant Asset Management LP, and Nuveen Asset Management LLC.
View insider buying and selling activity for NextCure
.

Which major investors are buying NextCure stock?

NXTC stock was bought by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, Federated Hermes Inc., Point72 Asset Management L.P., Asymmetry Capital Management L.P., Two Sigma Advisers LP, SG Americas Securities LLC, Swiss National Bank, and Vident Investment Advisory LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan.
View insider buying and selling activity for NextCure
.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $9.06.

How big of a company is NextCure?

NextCure has a market capitalization of $249.30 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

What is NextCure's official website?

The official website for NextCure is www.nextcure.com.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.